Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial Myelodysplastic syndromes (MDS) ...

Blood disorders known as myelodysplastic syndromes/neoplasms (MDS) are difficult to diagnose – and are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and other ...

Fatigue is one of the most common symptoms in myelodysplastic syndromes (MDS), and severe fatigue has been linked with less favorable mortality outcomes. Low blood cell counts (cytopenias) can drive ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...